Medtronic did not comment on the subpoena, but previously disclosed that it paid approximately $800,000 to Dr. Kuklo in consulting fees, the majority of which was given to him during the time he performed the Infuse study.
The study, which appeared in the British edition of the The Journal of Bone and Joint Surgery, found that Infuse performed significantly better at repairing leg injuries suffered by American combat soldiers in Iraq than a traditional bone graft. The study was recently challenged, and Dr. Kuklo has been accused of falsifying data.
Read the New York Times’ report on the Medtronic subpoena.
